ArticleVirchows Archiv : an international journal of pathology2026
Recurrent mTOR pathway alterations in renal cell carcinoma with hemangioblastoma-like features: A multi-institutional study of 9 cases with expanding morphologic spectrum.
Article in Virchows Archiv : an international journal of pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Renal hemangioblastoma (HB) is a rare extra-central nervous system mesenchymal neoplasm molecularly defined by recurrent mTOR pathway alterations and lacking VHL abnormalities, distinct from its central nervous system counterpart. While rare renal cell carcinomas (RCCs) exhibiting HB-like features have been documented, their clinicopathological spectrum, biological behavior, and molecular underpinnings remain incompletely characterized. This study characterizes a multi-institutional series of 9 cases of RCC with HB-like features. All tumors presented as well-circumscribed, solitary renal masses (median size, 2.6 cm), with 8 out of 9 cases demonstrating thick fibromuscular capsules. All cases uniformly lacked necrosis, mitotic activity, and vascular invasion. Histologically, the tumors demonstrated a variable proportion of the RCC component (5-50% tumor volume, mean:10%) with clear to pale eosinophilic cells forming tubules, acini, or tubulocystic structures blending with the dominant HB-like component; one case showed discrete compartmentalization of the RCC component, forming distinct papillary and tubulocystic structures adjacent to HB-like areas. Immunohistochemically, RCC components expressed epithelial markers (AE1/AE3, cytokeratin 7, CAM5.2), while HB-like components expressed stromal markers (α-inhibin, S100 protein). Critically, both components consistently expressed PAX8, vimentin, carbonic anhydrase IX, CD10, neuron-specific enolase, and GPNMB (8/9). Targeted next-generation sequencing revealed universal mTOR pathway alterations: mutually exclusive MTOR mutations (5 cases) or TSC2 mutations (4 cases), with no VHL alterations or 3p25 deletions identified. Over a median follow-up of 50 months (range, 4-114 months), all patients remained disease-free. Our study confirms that RCC with HB-like features represents a distinct morphological pattern within the HB to RCC with fibromyomatous stroma continuum and establishes its expanded morphological spectrum and indolent biological behavior.
Indexed as
Identifiers
41286520What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.